Dungog, Argie Lou .

HRN: 24-08-63  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/15/2023
CEFTRIAXONE 1G (VIAL)
11/15/2023
11/21/2023
IVT
2g
Od
Nephrotic Syndrome
Waiting Final Action 
11/15/2023
MUPIROCIN 2%, 15G (TUBE)
11/15/2023
11/21/2023
TOPICAL
Apply Thinly
Bid
Soft Tissue Injury
Waiting Final Action 
11/19/2023
MUPIROCIN 2%, 15G (TUBE)
11/19/2023
11/26/2023
TOPICAL
2%
BID
Staph Infection
Waiting Final Action 
11/21/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
11/21/2023
11/28/2023
IV
4.5g
Q8
Nephrotic Syndrome
Waiting Final Action 
11/22/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
11/22/2023
11/28/2023
IVT
4.5gm
Q8
Sepsis
Waiting Final Action 
11/30/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
11/30/2023
12/03/2023
IV
4.5g
Q8h
Pleural Effusion
Waiting Final Action 
12/04/2023
CLARITHROMYCIN 500MG (CAP)
12/04/2023
12/10/2023
PO
500mg
Bid
Pneumonia
Waiting Final Action 
12/11/2023
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
12/11/2023
12/18/2023
IV
1.5g
Q6hours
T/c Sepsis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: